AU2004268144A1 - Modified protease inhibitors - Google Patents

Modified protease inhibitors Download PDF

Info

Publication number
AU2004268144A1
AU2004268144A1 AU2004268144A AU2004268144A AU2004268144A1 AU 2004268144 A1 AU2004268144 A1 AU 2004268144A1 AU 2004268144 A AU2004268144 A AU 2004268144A AU 2004268144 A AU2004268144 A AU 2004268144A AU 2004268144 A1 AU2004268144 A1 AU 2004268144A1
Authority
AU
Australia
Prior art keywords
compound
conjugate
amino acid
peg
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004268144A
Other languages
English (en)
Inventor
Michelle Amaral
Mary J. Bossard
Robert C. Ladner
Arthur C. Ley
Michael J. Roberts
Aaron K. Sato
Yan Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dyax Corp
Nektar Therapeutics AL Corp
Original Assignee
Dyax Corp
Nektar Therapeutics AL Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp, Nektar Therapeutics AL Corp filed Critical Dyax Corp
Publication of AU2004268144A1 publication Critical patent/AU2004268144A1/en
Assigned to DYAX CORP., NEKTAR THERAPEUTICS AL, CORPORATION reassignment DYAX CORP. Alteration of Name(s) of Applicant(s) under S113 Assignors: DYAX CORP., NEKTAR THERAPEUTICS
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2004268144A 2003-08-29 2004-08-30 Modified protease inhibitors Abandoned AU2004268144A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49884503P 2003-08-29 2003-08-29
US60/498,845 2003-08-29
PCT/US2004/028256 WO2005021556A2 (en) 2003-08-29 2004-08-30 Modified protease inhibitors

Publications (1)

Publication Number Publication Date
AU2004268144A1 true AU2004268144A1 (en) 2005-03-10

Family

ID=34272739

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004268144A Abandoned AU2004268144A1 (en) 2003-08-29 2004-08-30 Modified protease inhibitors

Country Status (6)

Country Link
US (1) US20070020252A1 (https=)
EP (1) EP1663279A4 (https=)
JP (1) JP2007504169A (https=)
AU (1) AU2004268144A1 (https=)
CA (1) CA2537113A1 (https=)
WO (1) WO2005021556A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
ES2348230T3 (es) * 2002-06-07 2010-12-01 Dyax Corp. Prevención y reducción de la isquemia.
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
US20050089515A1 (en) * 2003-08-29 2005-04-28 Dyax Corp. Poly-pegylated protease inhibitors
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
WO2006070012A1 (en) * 2004-12-30 2006-07-06 Ingenium Pharmaceuticals Ag Agents useful in treating inflammatory bowel disease
PL1981519T3 (pl) * 2005-12-29 2018-07-31 Dyax Corp. Hamowanie proteaz
WO2007104541A2 (en) * 2006-03-16 2007-09-20 Dyax Corp. Compositions and methods using serine protease inhibiting peptides for treating ophthalmic disorders
WO2010033226A1 (en) * 2008-09-17 2010-03-25 Nektar Therapeutics Oligomer-protease inhibitor conjugates
US8637454B2 (en) 2009-01-06 2014-01-28 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
JP2012530069A (ja) * 2009-06-12 2012-11-29 ネクター セラピューティックス プロテアーゼ阻害剤、水溶性非ペプチドオリゴマーおよび親油性部分を含む共有結合体
US20110094080A1 (en) * 2009-10-27 2011-04-28 William Karales Bar soap support mat
SMT201800552T1 (it) 2010-01-06 2018-11-09 Dyax Corp Proteine che legano la callicreina plasmatica
KR102320178B1 (ko) 2011-01-06 2021-11-02 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
US10428158B2 (en) 2014-03-27 2019-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
EP3387018A1 (en) 2015-12-11 2018-10-17 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
EP4090427A1 (en) 2020-01-13 2022-11-23 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663143A (en) * 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
ATE277081T1 (de) * 1994-01-11 2004-10-15 Dyax Corp Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten
US5795954A (en) * 1994-03-04 1998-08-18 Genentech, Inc. Factor VIIa inhibitors from Kunitz domain proteins
NZ284766A (en) * 1994-06-02 1998-06-26 Merrell Pharma Inc Perfluoro amino ketones; medicaments as elastase inhibitors
US5589359A (en) * 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
US5990237A (en) * 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
EP1135493A2 (en) * 1998-11-30 2001-09-26 Eli Lilly And Company Erythropoietic compounds
CA2390292A1 (en) * 1999-11-12 2001-05-25 Maxygen Holdings Ltd. Interferon gamma conjugates
US6544760B2 (en) * 1999-12-22 2003-04-08 Zymogenetics, Inc. Kunitz domain polypeptide Zkun11
JP2004531550A (ja) * 2001-05-11 2004-10-14 アラダイム コーポレーション 吸入によって送達されるタンパク質の、分子性状の最適化方法および製剤
CZ20033182A3 (cs) * 2001-05-21 2004-09-15 Nektar Therapeutics Inzulínový prostředek a způsob podávání inzulínu
HRP20050024A2 (en) * 2002-07-24 2006-02-28 F. Hoffmann - La Roche Ag Pegylated t20 polypeptide
MXPA05000796A (es) * 2002-07-24 2005-04-19 Hoffmann La Roche Aditivos de acidos polialquilenglicolicos.
US7314613B2 (en) * 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
US20050089515A1 (en) * 2003-08-29 2005-04-28 Dyax Corp. Poly-pegylated protease inhibitors
US20060228331A1 (en) * 2003-10-10 2006-10-12 Novo Nordisk A/S IL-21 Derivatives and variants

Also Published As

Publication number Publication date
EP1663279A4 (en) 2009-02-18
CA2537113A1 (en) 2005-03-10
WO2005021556A3 (en) 2005-12-15
JP2007504169A (ja) 2007-03-01
EP1663279A2 (en) 2006-06-07
US20070020252A1 (en) 2007-01-25
WO2005021556A2 (en) 2005-03-10

Similar Documents

Publication Publication Date Title
AU2010257259B2 (en) Poly-PEGylated protease inhibitors
JP2007504170A5 (https=)
US20070020252A1 (en) Modified protease inhibitors
JP5632126B2 (ja) プロテアーゼ阻害
JP4137997B2 (ja) クニッツドメインから誘導されたヒトプラスミンの阻害剤
US20170189544A1 (en) Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
JP2006512050A (ja) 血清タンパク質結合標的特異的リガンドとその同定方法
JP2013533206A (ja) 炎症性障害のための、プロテアーゼ結合タンパク質を含む併用療法
US7514534B2 (en) Metalloproteinase-binding proteins
US20050164945A1 (en) Endotheliase-1 ligands
HK1092710B (en) Poly-pegylated protease inhibitors
HK1092710A (en) Poly-pegylated protease inhibitors

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application